Heat shock protein-peptide complex-96 (Vitespen) for the treatment of cancer

  • Robert J. Amato | ramato@tmhs.org The Methodist Hospital Research Institute Genitourinary Oncology Program Houston, United States.

Abstract

Heat shock proteins (HSPs) are the most abundant and ubiquitous soluble intracellular proteins. Members of the HSP family bind peptides, they include antigenic peptides generated within cells. HSPs also interact with antigen-presenting cells (APCs) through CD91 and other receptors, eliciting a cascade of events that includes re-presentation of HSP-chaperoned peptides by major histocompatability complex (MHC), translocation of nuclear factorkappaB (NFkB) into the nuclei, and maturation of dendritic cells (DCs). These consequences point to a key role of heat shock proteins in fundamental immunological phenomena such as activation of APCs, indirect presentation (or crosspriming) of antigenic peptides, and chaperoning of peptides during antigen presentation. The properties of HSPs also allow them to be used for immunotherapy of cancers and infections in novel ways. This paper reviews the development and clinical trial progress of vitespen, an HSP peptide complex vaccine based on tumor-derived glycoprotein 96.

Downloads

Download data is not yet available.
Published
2011-12-14
Section
Reviews
Keywords:
Cancer - Cross-priming - Dendritic cells - Heat shock proteins - Major histocompatability complex - Autologous tumor-derived
Statistics
Abstract views: 1075

FULL TEXT: 201
Share it
How to Cite
Amato, R. J. (2011). Heat shock protein-peptide complex-96 (Vitespen) for the treatment of cancer. Oncology Reviews, 2(1), 29-35. Retrieved from https://oncologyreviews.org/index.php/or/article/view/oncol.2008.29